Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair

PHASE3UnknownINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Inguinal HerniaPostoperative Pain
Interventions
DRUG

Bupivacaine HCl collagen-matrix implant

Placement of the bupivacaine collagen-matrix in the surgical site

DRUG

Bupivacaine HCl infiltration

Infiltration of the surgical site

Trial Locations (11)

15224

RECRUITING

Children's Hospital of Pittsburgh of UPMC (CHP-UPMC), Pittsburgh

32701

RECRUITING

Cornerstone Research Institute, Altamonte Springs

33144

WITHDRAWN

Medical Research Center, Miami

33165

WITHDRAWN

Elion & Volhard Pharmaceutical Research (E&V PR), Miami

75093

RECRUITING

Plano Surgical Hospital, Plano

77024

RECRUITING

Memorial Hermann Memorial City Medical Center, Houston

77054

WITHDRAWN

The Woman's Hospital of Texas, Houston

78411

RECRUITING

Driscoll Children's Hospital, Corpus Christi

79905

RECRUITING

El Paso Children's Hospital, El Paso

84124

ACTIVE_NOT_RECRUITING

Jean Brown Research, Salt Lake City

92653

RECRUITING

Alliance Research Centers, Laguna Hills

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Innocoll

INDUSTRY

NCT03262688 - Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair | Biotech Hunter | Biotech Hunter